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The Nell-1 Growth Factor Stimulates Bone Formation
by Purified Human Perivascular Cells
Xinli Zhang, M.D., Ph.D.,1,2 Bruno Pe´ault, Ph.D.,3 Weiwei Chen, Ph.D.,1 Weiming Li, M.D.,1
Mirko Corselli, Ph.D.,3 Aaron W. James, M.D.,1,2 Min Lee, Ph.D.,4 Ronald K. Siu, M.S.,5 Pang Shen,3
Zhong Zheng, Ph.D.,3 Jia Shen, Ph.D.,1 Jinny Kwak, D.D.S.,2 Janette N. Zara, M.D.,3 Feng Chen, Ph.D.,1
Hong Zhang, D.D.S.,1 Zack Yin, D.D.S., Ph.D.,1 Ben Wu, D.D.S., Ph.D.,5
Kang Ting, D.M.D., DMedSci,1–3,* and Chia Soo, M.D.3,*
The search for novel sources of stem cells other than bone marrow mesenchymal stem cells (MSCs) for bone
regeneration and repair has been a critical endeavor. We previously established an effective protocol to homo-
geneously purify human pericytes from multiple fetal and adult tissues, including adipose, bone marrow, skeletal
muscle, and pancreas, and identified pericytes as a primitive origin of human MSCs. In the present study, we
further characterized the osteogenic potential of purified human pericytes combined with a novel osteoinductive
growth factor, Nell-1. Purified pericytes grown on either standard culture ware or human cancellous bone chip
(hCBC) scaffolds exhibited robust osteogenic differentiation in vitro. Using a nude mouse muscle pouch model,
pericytes formed significant new bone in vivo as compared to scaffold alone (hCBC). Moreover, Nell-1 significantly
increased pericyte osteogenic differentiation, both in vitro and in vivo. Interestingly, Nell-1 significantly induced
pericyte proliferation and was observed to have pro-angiogenic effects, both in vitro and in vivo. These studies
suggest that pericytes are a potential new cell source for future efforts in skeletal regenerative medicine, and that
Nell-1 is a candidate growth factor able to induce pericyte osteogenic differentiation.
Introduction
Stem cell research is a key driving force in the field ofmodern regenerative medicine. Identification and valida-
tion of new stem cell sources for tissue regeneration remains a
critical part of these evolving endeavors.1 Bone regeneration is
critical to fracture repair as well as to healing of bone grafts
used during spine, craniofacial, dental, post-trauma, and post-
tumor reconstruction. However, current therapies either have
high donor-site morbidity (e.g., bone autografts), limited ef-
ficacy (e.g., bone allografts), or are accompanied with unde-
sirable or even severe adverse effects (e.g., treatments with
bone morphogenetic proteins [BMPs]).2–4 The highly orches-
trated process of successful bone regeneration requires an
optimal microenvironment specifically enriched with stem
cells of osteogenic potential, osteoinductive growth factors,
and suitable scaffolds to facilitate the regeneration of func-
tional bone in the appropriate locations.1,5
Current conventional stem cell sources have significant
drawbacks. Low stem cell numbers limit the use of fresh
autologous bone marrow,6,7 whereas the long culture deri-
vation times hamper the use of bone marrow mesenchymal
stem cells (BMSCs) or adipose-derived stem cells (ASCs).
Although the use of the noncultured total stromal vascular
fraction (SVF) from adipose tissues may remove the need for
culture, available studies using SVF show lower bone re-
generation efficacy relative to cultured ASCs.8–10 Moreover,
significant cell heterogeneity, including high numbers of
nonstem cells, nonviable cells, and the presence of differen-
tiation inhibiting endothelial cells11,12 make the use of adi-
pose total SVF less desirable. Thus, identification of readily
available stem cell sources and development of well-defined
stem cell differentiation protocols that comply with FDA
regulatory requirements for product safety, purity, and potency
comprise critical barriers to overcome before widespread ap-
plication of cell-based regenerative medicine strategies.1,13
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To directly address the issues related to stem cell avail-
ability, purity, and potency, we previously described the
prospective purification of the perivascular ancestors of
human MSC through fluorescence activated cell sorting
(FACS) and delineated the native origins of at least some of
these cells as being associatedwith capillaries andmicrovessels
(i.e., pericytes).14 This ability to prospectively isolate and
characterize human multipotent stem cells, based on defined
cell surface markers without need for culture, is significant due
to the widespread tissue distribution of these cells, enabling
large availability for autologous tissue engineering.15 For in-
stance, our unpublished data on uncultured perivascular stem
cell yields from the SVF of human lipoaspirate samples agree
with publishedASCyields.6,16,17Moreover,we have confirmed
that human perivascular cells sorted from diverse human
tissues and cultured as single clones can give rise to adher-
ent, multilineage progenitor cells that exhibit the features of
MSC.14 We show that these purified perivascular cells ex-
hibit defined identity (CD146+ , NG2+ , PDGF-Rb+ , CD34- ,
CD45- , CD31- , CD56- ) and purity. Importantly, purified
perivascular cells also exhibit defined potency with respect
to cell population doubling, in vitro chondrogenesis, in vitro
adipogenesis, in vitro and in vivo myogenesis, and in vivo
BMP-2 stimulated osteogenesis.14 Interestingly, the purified
perivascular cells also secrete more pro-angiogenic factors such
as basic fibroblast growth factor and vascular endothelial
growth factor (VEGF) than classically derived ASCs.18
It has been noted for decades, by ultrastructural analysis
of regenerates, that these perivascular cells are actively in-
volved in bone regeneration processes19 and play critical
roles in regulating endothelial cell function and angiogene-
sis.20,21 However, it is unclear from our previous study if
these implanted perivascular cells, as a novel source of stem
cells, actually persist in vivo to differentiate and actively
participate in angiogenesis and new bone formation. To
better define the in vivo potency of this novel stem cell
source, we describe here detailed tracking studies to deter-
mine the fate of the implanted human perivascular cells in
the severe combined immunodeficient (SCID) mouse thigh
muscle.
To ensure appropriate perivascular cell differentiation, we
added Nell-1, a growth factor with novel osteoinductive
properties. Animals deficient in functional Nell-1 demon-
strate defects in skeletal22 and vascular development (article
in submission). For the past decade, the osteoinductivity of
Nell-1 has been investigated and well-documented in several
small and large animal models.23–26 It is noteworthy that
when injected into nude mouse muscle, Nell-1 promotes goat
BMSC to regenerate bone that is structurally similar to native
compact bone, whereas BMP2 induces a large hollow bone
mass filled with fatty marrow tissue.27
In this present study, we use a model in which Nell-1
alone does not stimulate osteogenesis,28 that is, mouse in-
tramuscular transplantation, to definitively demonstrate that
homogenously purified human pericytes possess significant
osteogenic potential and that Nell-1 stimulation significantly
enhances their proliferative, osteogenic, and angiogenic
capacities during bone regeneration. Thus, the successful
use of prospectively isolated human purified pericytes with
Nell-1 is a proof of principle that critical clinical and regu-
latory barriers to musculoskeletal regenerative medicine can
be addressed.
Materials and Methods
Purification of pericytes from human fetal pancreas
Pericytes were isolated from human fetal pancreas, known
to house abundant pericytes.14 Human fetal tissues were
obtained following voluntary or therapeutic pregnancy in-
terruptions performed at Magee-Womens Hospital (Uni-
versity of Pittsburgh), in compliance with Institutional
Review Board protocol # 0506176. A single human fetus was
used for the data presented herein. Using FACS, distinct
microvessel pericytes (CD146 + , CD34 - , CD45- , CD56- )
were isolated and then expanded in vitro. The antibodies for
cell sorting include CD146 (AbD Serotec), CD34 and CD56
(BD Biosciences), and CD45 (Santa Cruz Biotechnology, Inc.).
The purified pericytes were maintained in growth medium:
F12–Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum and 1·penicillin–streptomycin
(Gibco). MSC markers were validated by flow cytometry
throughout the cell expansion process. All experiments were
done with passage 10 to 12 pericytes.
In vitro proliferation and osteoblastic differentiation
of human pericytes stimulated with rhNell-1
Pericytes were cultured at low seeding density (2· 103/
well) in 96-well plates in the presence or absence of rhNell-1
(Aragen Bioscience) at 100 and 800 ng/mL for 7 days. Cel-
lular proliferation was assayed every other day with MTT
(Promega Corporation) in triplicate. For osteogenic differ-
entiation, 1.5 · 105 pericytes per well were seeded in 24-well
plates and cultured in growth medium supplemented with
50 mg/mL ascorbic acid and 10mM beta-glycerol phospha-
tase. rhNell-1 at 100 and 800 ng/mL was added upon
cell confluence and the fresh medium containing rhNell-1
was replenished every 3 days. Gene expression of osteo-
blastic cell markers, including Runt-related transcription factor-
2 (Runx2), Osterix (Osx), and osteocalcin (OCN) was detected
at days 0, 3, 6, 9, and 12 poststimulation with rhNell-1 by
real-time polymerase chain reaction (PCR) as stated in our
previous work.26 Gene expression of peroxisome proliferator-
activated receptor c (PPARc) and VEGF was also detected by
real-time PCR. The specific primers for real-time PCR were
from TaqMan gene expression assays (Applied Biosystems).
Mineralization was quantified by alizarin red staining as
reported previously.28
Induction of pericyte mineralization
on three-dimensional human cancellous
bone chip scaffolds
A commercial human cancellous bone chip (hCBC) prep-
aration (MTF) consisting of minimally processed hCBC
mixed with demineralized bone matrix was used as a scaf-
fold. About 2.5 · 105 pericytes were labeled with lentiviral
green fluorescent protein (GFP) and seeded onto the surface
of an hCBC scaffold that was supported by a Millicell culture
insert (Millipore Corporation) in 24-well plates with mini-
mum volume of growth medium. The same osteogenic dif-
ferentiation media used for in vitro studies were supplied for
this three-dimensional (3D) culture system after 2 h of cell
seeding. The distribution and viability of seeded cells on
hCBC were monitored by the morphology of GFP-positive
cells. The fresh medium containing rhNell-1 at 100 ng/mL
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was replenished every other day. The degree of mineraliza-
tion was assessed using alizarin red staining described pre-
viously.28 Images were obtained using an Olympus SZX12
fluorescence stereo microscope and an Olympus IX71 fluo-
rescence inverted microscope.
Intramuscular implantation in SCID mice of pericytes
loaded on hCBC with or without rhNell-1 preparation
of implant
Each 15, 100, or 300 mg rhNell-1 protein total dose was
lyophilized onto 50mg tricalcium phosphate (TCP) particles
200–300 mm in diameter and stored at 4C. The pericytes
were labeled with RKH red fluorescent cell tracking dye
(Sigma-Aldrich Co.) following manufacturer’s instruction.
Before implantation, the rhNell-1-loaded TCP was mixed
well with hCBC carrier mechanically, and then 20mL of
2.5 · 105 prelabeled pericyte suspension was dropped onto
the mixed scaffold with gentle stirring to achieve a final
volume of 100mL for each implant. For live optical imaging
experiments, pericytes were transduced with lentiviral lu-
ciferase instead of fluorescent labeling and mixed with hCBC
before implantation into mouse thigh muscle. Treatment
groups are further delineated in Table 1.
Surgical procedure
A muscle pouch implant in SCID mice was used to in-
vestigate ectopic bone formation. Twenty-four 6-week-old
SCID mice were evenly and randomly divided into six ex-
perimental groups corresponding to the hCBC implant
groups described (further delineated in Table 1). Thus, a total
of four mice (or n = 8 muscle pouch implants) were per-
formed per experimental group. Animals were anaesthetized
by isoflurane inhalation (5% induction; 2% maintenance) and
premedicated with 0.05mg/kg buprenorphine.
Bilateral incisions in the hindlimbs were made, and
pockets were cut in the biceps femoris muscles by blunt
dissection, parallel to the muscle fiber long axis. For each
mouse, 100 mL of material was implanted into each muscle
pouch (2 sites) for a total of 200 mL per mouse. The fasciae
overlying the muscle were sutured with a simple continuous
pattern and the skin was closed in a separate layer using 4-0
or 5-0 Vicryl sutures in a subcuticular pattern. Animals were
postoperatively treated with buprenorphine for 48 h and
trimethorprim/sulfamethoxazole for 10 days for pain man-
agement and antibiotics, respectively. Animals were housed
and experiments were performed in accordance with
guidelines of the Chancellor’s Animal Research Committee
of the Office for Protection of Research Subjects at the Uni-
versity of California, Los Angeles.
Pericyte tracking after implantation
Pericytes expressing luciferase driven by a cytomegalo-
virus promoter were observed at 1, 2, and 3 weeks post-
operation in mice from each experimental group.
Bioluminescence imaging was performed using an IVIS Lu-
mina II device (Caliper Life Sciences). Light outputs were
quantified using Living Image software (version 2.5, Xeno-
gen) as an overlay on Igor Pro imaging analysis software
(WaveMetrics). Total light output, in photons/second/cm2/
steradian, was normalized to the integration time, the dis-
tance from the camera to the animal, the instrument gain,
and the solid angle of measurement to provide for cross-
platform comparison. Imaging was quantified by creation of
circular regions of interest (ROIs) over each femur.
High-resolution quantitative microCT analysis
Samples were scanned using high-resolution micro-CT
(Skyscan 1172F, Skyscan) at an image resolution of 19.73mm
(100 kV and 100mA radiation source, using a 0.5mm alu-
minum filter) and analyzed using DataViewer, Recon, CTAn,
and CTVol software provided by the manufacturer. All
quantitative and structural morphometric data use nomen-
clature described by the American Society for Bone and
Mineral Research Nomenclature Committee.29
For 3D data analysis, ROI of diameter 7.18mm were taken
through the entire length of the scanned sample to quantify
bone volume (BV). A value of 25 was selected as the optimal
threshold that includes all mineralized tissue but excludes
muscle and soft tissue in the scanned region. Sparsely min-
eralized bone tissue was further excluded by increasing the
threshold value to 35 using a global thresholding procedure
as described.30,31 We designated the difference in BV ob-
tained between thresholds 25 and 35 as the ‘‘volume of rel-
atively new bone.’’ Student’s t-test was used to assess
statistical difference in BV of the five experimental groups.
3D images were reconstructed for each threshold level and
superimposed to separately represent all mineralized tissue
from sparsely mineralized bone, and to highlight the volume
of relatively new bone.
Histology and immunohistochemistry analysis
The decalcified tissues were embedded in paraffin. De-
paraffinized sections were used for all histology and im-
munostaining. HE and trichrome staining were completed
following standard protocols. Immunohistochemistry was
performed with primary antibodies against bone sialoprotein
(BSP) (Chemicon International), von Willebrand factor (vWF)
(Abcam Inc.), VEGF, and MHC Class I antigen (Santa Cruz
Biotechnology, Inc.) using the ABC (Vector Laboratories,
Table 1. Treatment Groups
Treatment Scaffold rhNell-1 Pericytes n (implants)
Carrier Alone hCBC (100 mL) 50mg TCP alone None 8
Nell-1 Alone hCBC (100 mL) 15mg Nell-1 in 50mg TCP None 8
Pericyte Alone hCBC (100 mL) 50mg TCP alone 2.5 · 105 in 20 mL 8
Pericyte +Nell-1 hCBC (100 mL) 15mg Nell-1 in 50mg TCP 2.5 · 105 in 20 mL 8
Pericyte +Nell-1 hCBC (100 mL) 100 mg Nell-1 in 50mg TCP 2.5 · 105 in 20 mL 8
Pericyte +Nell-1 hCBC (100 mL) 300 mg Nell-1 in 50mg TCP 2.5 · 105 in 20 mL 8
hCBC, human cortical/cancellous bone chip; TCP, tricalcium phosphate.
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Inc.) method. Frozen sections used for in situ human pericyte
tracking were counterstained with Hoechst 33324 (Sigma-
Aldrich Co.). The histological images were obtained on an
Olympus BX51 fluorescence microscope. Semi-quantitative
histomorphometric analysis of H&E, vWF, and VEGF stains
was performed as previously described.32
Statistical analysis
Statistical analysis was performed using an appropriate
analysis of variance (ANOVA), followed by post hoc analysis
between specific groups. A Bonferroni adjustment was per-
formed to ensure significance when multiple groups were
examined. For data presented in 1B, a one-factor ANOVA
was used (treatment type), whereas in all other figures a two-
factor ANOVA was used (treatment type and time in days).
Results
Nell-1 enhances human fetal pericyte proliferation
and osteoblastic differentiation in vitro
In the current study, human fetal pancreatic perivascular
cells at passages 10 to 12 were used for all experiments. To
determine the effect of Nell-1 on proliferation, perivascular
cells were stimulated with rhNell-1 at 100 and 800 ng/mL
under regular growth culture conditions. Both dosages induced
significantly greater proliferative activity as early as 3 days
poststimulation (Fig. 1A). Functionally, rhNell-1 also signifi-
cantly increased the mineralization of pericytes as revealed by
alizarin red staining (Fig. 1B). To gain insight into pericyte os-
teoblastic differentiation induced by rhNell-1, the expression of
the major osteoblastic cell markers Runx2, Osx, and OCN as
well as the adipogenic differentiation gene PPARc were evalu-
ated using real-time PCR (Fig. 1C). In response to Nell-1 stim-
ulation, Runx2 and Osx expression levels transiently decreased
in the early phase (day 3), elevated at the mid phase (day 6
and/or day 9), and then returned to low levels as mineraliza-
tion occurred. Nell-1 stimulation also upregulated Ocn expres-
sion at both early and late stages. In contrast, the adipogenic
master transcriptional factor PPARc expression was signifi-
cantly reduced at day 9. To investigate the compatibility of
pericytes and hCBC scaffold carrier, the osteoblastic differenti-
ation of pericytes cultured on hCBC was quantified by alizarin
red staining at day 15 after rhNell-1 stimulation. The degree of
mineralization was greatest in pericytes+hCBC+ rhNell-1
groups, followed by pericytes+hCBC (Fig. 1D). These data
demonstrate that pericytes undergo osteogenic differentiation in
3D scaffolds, and that rhNell-1 stimulation significantly en-
hances osteogenic, while inhibiting adipogenic gene expression.
Nell-1 promotes pericyte osteochondrogenic
differentiation and endochondral bone formation in vivo
We next examined the effects of rhNell-1 on bone formation
by perivascular cells in vivo. Because Nell-1 can promote bone
formation in many osseous defect models, we specifically
utilized a muscle pouch implantation model in which Nell-1
alone was unable to promote bone formation without adding
exogenous osteoprogenitor cells.27,28 This allowed a more di-
rect assessment of human pericyte osteogenic potential when
in the presence and absence of rhNell-1. Fixed-volume 100mL
implants in different treatment groups were implanted into
thigh muscles of immunodeficient mice. Histology revealed
clear differences in endochondral bone formation as early
as 2 weeks postimplantation. hCBC alone and hCBC+ 15mg
rhNell-1 samples manifested very limited chondrogenesis
(Fig. 2A–F), whereas the hCBC+pericytes group exhibited
robust chondrogenesis (Fig. 2G–I). Meanwhile, hypertrophic
cartilage with mineralized matrix surrounding marrow-like
cells was readily detectable in hCBC+pericytes+ 15mg rhNell-
1 samples (Fig. 2J–L). To further explore rhNell-1’s role in
promoting bone regeneration by hCBC+pericytes, higher
rhNell-1 doses of 100 and 300mg were also tested in addition
to rhNell-1 at 15mg. At 4 weeks postimplantation, there was
abundant new bone formation surrounding almost every
hCBC particle with intense positive BSP staining in the higher
dose rhNell-1 groups, whereas rhNell-1 at 15mg promoted a
lesser amount of bone generation (Fig. 2M–R).
Quantitative microCT analysis at 4 weeks revealed distinct
differences in new bone formation. Isolated hCBC particles
demonstrated minimal connectivity, whereas hCBC+ rhNell-1
and hCBC+pericytes regenerates exhibited increased particle
consolidation that was accompanied by increased new bone in
hCBC+ rhNell-1, and, interestingly, decreased new bone for-
mation in the hCBC+pericytes group (Fig. 3A–C, F). In con-
trast, both the 15 and 300mg hCBC+pericytes+ rhNell-1
samples demonstrated significantly increased hCBC particle
consolidation as well as new bone formation (Fig. 3D–F). These
data indicate that Nell-1 coupled with responsive stem cells, such
as pericytes, markedly accelerated chondrogenic and osteogenic
differentiation and increased new bone formation. In addition,
histomorphometric analysis of serial histological sections dem-
onstrated a significant increase in bone formation, especially
among pericyte+ rhNell-1 groups (Fig. 3G). The significant de-
crease in new bone formation in the hCBC+pericytes group
relative to hCBC alone was unexpected, and suggests that
rhNell-1, beyond supporting perivascular stem cell differentia-
tion (Fig. 2J–R) and proliferation (Fig. 1A), may also support
perivascular stem cell survival. Decreased new bone formation
in the hCBC+ rhNell-1 vs. hCBC+pericytes+ rhNell-1 samples is
consistent with our earlier in vitro observations of lesser cell
numbers and/or decreased osteogenic response of retained
hCBC cells relative to purified perivascular cells (Fig. 1D).
Nell-1 promotes engraftment and tissue integration
of purified pericytes in vivo
To directly assess the impact of Nell-1 on purified peri-
vascular cells in vivo, the pericytes were transduced with
FIG. 1. Enhanced in vitro proliferation and osteoblastic differentiation of purified human perictyes with Nell-1 stimulation.
(A) Significantly increased pericyte proliferation was seen with Nell-1 stimulation. (B) Pericytes underwent mineralization in
osteoblastic differentiation medium and this potential was significantly enhanced by Nell-1. (C) Real-time polymerase chain
reaction of osteoblastic marker genes Runx2, Osx, and Ocn as well as adipogenic marker gene PPARc during pericyte
osteoblastic differentiation. (D) Pericyte mineralization on three-dimensional hCBC scaffold evaluated by Alizarin red
staining. Scale bars: 1mm for (a, c, e, g) images from a stereo microscope and 100mm for (b, d, f, h) images from an inverted
microscope. hCBC, human cancellous bone chip. Color images available online at www.liebertonline.com/tea
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lentiviral luciferase before implantation with hCBC or
hCBC+ rhNell-1 into mouse thigh muscles for detailed track-
ing studies. Luciferase activity was monitored by weekly
optical imaging for 3 weeks. Bioluminescence imaging dem-
onstrated optical signals largely confined to the implant vi-
cinity. Excitingly, signal intensity from the transduced
pericytes increased in an rhNell-1 dose-dependent fashion.
Relative to no rhNell-1, signal intensity was 15.2-fold higher in
the 300mg and 6.3-fold higher in the 15mg groups at 6 days.
High signal levels persisted in the 300mg group for at least 21
FIG. 2. Histology of bone
regenerates with involvement
of purified pericytes and
Nell-1. (A–F) Only small
amounts of cartilaginous
tissue (arrows) formed in
hCBC alone and hCBC +
rhNell-1 implants without
loaded pericytes at 2 weeks
postoperation. (G–L) Large
amount of cartilaginous
tissue and focal mineralized
woven bone (arrows) formed
in pericyte-loaded hCBC
implants with even more
mineralized bone with Nell-1
presence. (M–R) At 4 weeks
postoperation, new bone
formation with bone
sialoprotein positive staining
(arrows) occurred at almost
every pericyte-loaded hCBC
scaffold implant with the
higher rhNell-1dose. Scale
bars: 100mm for A, D, G, and
J; 50 mm for B, C, E, F, H, I, K,
L, N, O, Q, and R; and
250 mm for M and P. Color
images available online at
www.liebertonline.com/tea
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days (Fig. 4A, B). These data indicate that Nell-1 promotes
either pericyte survival, engraftment, and/or proliferation,
and are consistent with in vitro data showing Nell-1 en-
hancement of pericyte proliferation (Fig. 1A)
Tissue integration of the human pericytes was also inves-
tigated by prestaining the cells with RKH, a red fluorescent
live cell labeling dye, before implantation. At 4 weeks post-
implantation, the prestained pericytes were still clearly visible
in areas of active regeneration and mineral deposition on the
surface of hCBC particles (Fig. 5A–F) (yellow arrows) as well
as in perivascular areas next to endothelial cells (Fig. 5G–I)
(red arrows). To further confirm the relative contribution of
engrafted RKH+pericytes to blood vessel formation, we
stained for CD31 on endothelium and superimposed with
RKH labeling images (Fig. 5J–L). Staining with the endothelial
cell marker CD31 confirmed that pericytes are also found in
close association to blood vessels, therefore recapitulating
their original localization. These data conclusively demon-
strate human pericyte engraftment, persistence, and integra-
tion in and around new bone tissue.
Nell-1 stimulates angiogenic effects in pericytes
at early stages of bone regeneration
Pericytes interact with endothelial cells to stabilize newly
formed endothelial tubes and regulate endothelial cell prolif-
eration, differentiation, migration, and survival. Hence, the
participation of pericytes in angiogenesis is not unexpected.
One intriguing question, however, is whether Nell-1 can en-
hance the angiogenic function of purified perivascular cells.
Besides defects in skeletal development,22 functionally Nell-1-
deficient mouse embryos also exhibit defective vasculogenesis
during mid-gestation (personal communication from Dr.
Cymbeline Culiat). Interestingly, when human pericytes were
maintained in osteogenic differentiation medium, rhNell-1
was capable of further upregulating VEGF expression starting
at day 6 and throughout the study period (Fig. 6A). In vivo
angiogenic function of the pericyte+ rhNell-1 combination
was assessed by histology and vWF endothelial staining
of hCBC+pericytes– rhNell-1 specimens at 1 week post-
implantation, a time shown to be optimal for monitoring
in vivo angiogenesis.33 The hCBC+pericytes+ rhNell-1 group
exhibited relatively higher capillary and small blood vessel
numbers and density in the granulation tissues surrounding
the hCBC particles as well as significantly more positive vWF
endothelial staining relative to the hCBC + pericytes group.
Specifically, vWF staining intensity was assessed by histo-
morphometric analysis of serial sections (n= 4 per group),
showing a clear and abundant increase in relative staining
intensity with pericyte addition to hCBC. (Fig. 6B–F). Mean-
while, VEGF immunohistochemistry was performed on sam-
ples at 2 weeks postimplantation. VEGF staining was
FIG. 3. MicroCT analysis of new bone regeneration. (A) Scattered and isolated hCBC scaffold particles (in gray) were observed
in hCBC alone implants with some new bone (in red). (B, C) Increased hCBC particle convergence and small cluster formation
when rhNell-1 was applied with hCBC (B) or when pericytes were loaded onto hCBC (C). (D, E) Significant hCBC particle
convergence forming large clusters with obvious new bone formation (in red) when pericyte-loaded hCBCwas applied together
with rhNell-1. (F)Quantitation of new bone formation among different treatment groups, *p< 0.05 versus groupA of hCBC alone
andNS: no significant difference. Scale bars: 2mm. (G)Histomorphometric analysis of bone formation, represented as pixels bone
by H&E staining per high-power field, n= 10 per group. Color images available online at www.liebertonline.com/tea
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localized mainly to the periphery along hCBC particles and
the stromal tissues surrounding active bone formation sites
(Fig. 6G–I). Notably, the hCBC controls exhibited only low
levels of VEGF staining, whereas the pericyte groups dem-
onstrated abundant VEGF signals with highest signals in the
hCBC+pericytes+ rhNell-1 group (Fig. 6I). The semi-quanti-
tation analysis showed a 139% increase in staining intensity
among pericyte engrafted groups (means 9907 pixels, 23,762
pixels, and SDs 3657, 8457, respectively), and a 186% increase
among pericyte+ rhNell-1 groups (means 9907 pixels, 28,317
pixels, and SDs 3657, 13,048, respectively; n= 4 per group). To
determine if the VEGF signals originated from the implanted
human cells or host murine cells and to document the spatial
relationship between VEGF signals and implanted pericytes,
serial tissue sections used for VEGF immunostaining were
further labeled with an anti-human MHC Class I antibody.
MHC Class I–positive pericytes, indicating human origin,
were localized in areas of high VEGF staining (Fig. 6J–L).
However, the significantly more prevalent distribution of
VEGF signals, relative to that of human pericytes, indicates
that the host stromal cells are also involved in production
of VEGF. These data demonstrate that implanted human
FIG. 4. In vivo tracking of
human pericytes implanted
intramuscularly in SCID
mice. (A) Panel of optical
images was obtained at
different time points for
tracking human pericytes
transduced with lentiviral
luciferase after implantation
in thigh muscles of SCID
mice. Notably, the signals
were remarkably higher in
rhNell-1 groups in a
dose-dependent manner.
(B) Quantitation of the optical
signals from implanted
human pericytes among
different treatment groups.
SCID, severe combined
immunodeficient; TCP,
tricalcium phosphate. Color
images available online at
www.liebertonline.com/tea
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pericytes possess angiogenic and trophic properties that are
significantly enhanced by rhNell-1 during bone regeneration.
Discussion
Pericytes—or mural cells—are closely associated anatom-
ically with endothelial cells in the walls of capillaries and
microvessels in all vascularized tissues throughout the
human body. Arguably, pericytes may represent a primitive
origin of hMSC since they share phenotypic traits with
MSC,34–38 express all the markers of hMSC in situ, and are
indistinguishable from conventionally derived hMSC after
purification to homogeneity and cultivation in vitro.14,39 Peri-
cytes purified from different human tissues possess similar, if
not identical, multipotency for inducible differentiation into
FIG. 5. Tissue engraftment of implanted human pericytes into regenerates. (A) Images of implants without loaded human
pericytes onto hCBC showed cell nucleus stained with Hoechst 33342 (in blue). (B) The RKH live cell dye prelabeled human
pericytes (in red) were clearly visible in the implants of pericyte-loaded hCBC groups at 4 weeks postintramuscular im-
plantation. (C) Higher magnification of image B. (D) Prelabeled human pericytes (in red) in hCBC + rhNell-1 implants. (E)
Phase-contrast imageD showing hCBC particles outlined in yellow lines and tissue profile. (F) Superimposed image ofD and
E showing implanted pericytes engrafted into remodeling hCBC scaffolds (yellow arrows). (G–I) Prelabeled human pericytes
not only engrafted into remodeling hCBC scaffolds (pink arrows), but also participated in vascularization (yellow arrows). (J–
L) Prelabeled pericytes combined with CD31 immunohistochemistry (in green), showing colocalization (yellow arrows). Scale
bar: 50mm for A and B, and 25 mm for C–I.
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FIG. 6. Angiogenic effects of purified human pericytes during osteoblastic differentiation in vitro and in vivo. (A) VEGFmRNA
expression of purified pericytes was significantly enhanced with rhNell-1 stimulation during osteoblastic differentiation. (B, C)
HE and vWF immunohistochemistry in hCBC + pericytes + PBS samples. (D, E) HE and vWF immunohistochemistry in
hCBC + pericytes + rhNell-1 samples. (F) Semi-quantification of vWF immunostaining. (G–I) Immunohistochemistry of VEGF
(arrows) in 2 week samples from indicated treatment groups. ( J–L) Immunohistochemistry of human MHC Class I showing
implanted human pericytes in 2-week samples from indicated treatment groups. Scale bar: 50mm for B–E and G–L. *p< 0.05,
**p< 0.01. Black arrows and arrowheads indicate regions of positive staining. VEGF, vascular endothelial growth factor; vWF,
von Willebrand factor. Color images available online at www.liebertonline.com/tea
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myogenic, adipogenic, chondrogenic, and osteogenic cell
lineages.14,18 Notably, BMSC and muscle derived stem cells
may also contain a fraction of perivascular cells as they have
all exhibited robust osteogenic potential in previous re-
ports.40–42 In our present study, we utilized the pericytes
derived from tissues (i.e., pancreas) not typically associated
with bone formation to illustrate their osteogenic potential.
The data shown here not only validate the in vitro osteo-
genicity of human pericytes derived from pancreas, but also
definitively demonstrate their in vivo angiogenic and tro-
phic effects. Specifically, the osteogenic capacity of purified
human pericytes was strongly evidenced by Runx2, Osx, and
Ocn gene expression and mineralization in vitro, whereas
VEGF production in osteoblastic differentiation medium
confirmed their concomitant angiogenic properties. In vivo,
the pericytes also demonstrated their capacity for tissue en-
graftment and trophic effects through, in part, VEGF pro-
duction and by induction of VEGF production by host cells.
Remarkably, Nell-1 stimulation significantly promoted
pericyte survival/engraftment as well as angiogenic and
osteogenic properties. Interestingly, Nell-1 was mitogenic for
human pericytes, in contrast to other cell types,27,43,44 indi-
cating that Nell-1-induced proliferation is cell and/or dif-
ferentiation state dependent. Nell-1 mitogenic effects on
human pericytes may also account for much higher lucifer-
ase signals and increased bone regeneration volumes in the
mouse muscle pouch. In general, stem cells do not form bone
unless they are precultured under osteogenic conditions or
treated with osteoinductive factors.45 Since Nell-1 repro-
ducibly induced bone regeneration in various small and
large animal studies,23–26 the use of rhNell-1 ensures an ap-
propriate proliferative and osteoinductive microenvironment
for bone growth from purified human pericytes delivered on
hCBC scaffolds. Nevertheless, the utilization of the intra-
muscular transplantation mouse model not only remarkably
simplifies, but also improves data interpretation in defining
the osteogenic property of human pericytes with and with-
out Nell-1 enhancement in vivo. rhNell-1 presence markedly
upregulated Runx2, Osx, and Ocn gene expression and
mineralization in pericytes. Nell-1 is a highly osteospecific
molecule that is directly regulated by Runx2, the master
regulatory gene for osteoblast differentiation.46
rhNell-1 also significantly enhanced the inherent angio-
genic property of pericytes. In vitro and in vivo VEGF pro-
duction by human pericytes as well as angiogenesis were
greatly upregulated in the presence of Nell-1. Improved an-
giogenesis in rhNell-1 +pericyte groups likely contributed to
more effective bone regeneration as the osteogenic-angiogenic
interface in bone biology is well described.47 Consistent with
this, enhanced osteogenesis, ascribed to increased VEGF se-
cretion, was observed in human umbilical vein endothelial
cells and human osteoprogenitor (HOP) cells co-cultures rel-
ative to HOP monocultures.48 Meanwhile, the co-application
of adenoviral VEGF-transduced ADSC with endothelial pro-
genitor cells also significantly improved bone repair in vivo.49
Lastly, the observed human pericyte engraftment into small
blood vessels in the regenerates further supports the signifi-
cant role of vascular ingrowth and angiogenesis in promoting
bone regeneration in our pericyte/rhNell-1 implant models.
Overall, our data offer direct experimental evidence that Nell-
1 enhances VEGF expression and angiogenesis during bone
regeneration.
Advantages of using homogenously purified human
pericytes (CD146 + , CD34- , CD45 - , CD56- ) over con-
ventional hMSC include but are not limited to: (1) precise
characterization in terms of native tissue localization, phe-
notype, and developmental potential, whereas the most fre-
quently used hMSC are from bone marrow (BMSC) and are
retrospectively derived from primary, heterogeneous cell
cultures based on their plastic adherence property; (2) no ex
vivo culture of purified pericytes is absolutely required, but
these pericytes can be expanded into large amounts in a
short time in vitro without alteration of their MSC charac-
teristics,14 whereas BMSC have to be cultivated and pas-
saged at very limited numbers in plastic vessels in vitro over
certain periods before being applicable; (3) improved trophic
potency over classically derived adipose tissue and cord
blood MSC18; and (4) the inherent function of pericytes in
regulating endothelial cell proliferation, differentiation, sur-
vival, and capillary tube formation to promote angiogenesis
and tissue ingrowth during regeneration. Practically, the
collection of highly purified human pericytes and its long-
term storage in liquid nitrogen, much like cord blood, pe-
ripheral blood, or bone marrow, could be expected for future
use in personalized reparative and regenerative medicine of
the skeleton as well as other mesodermal tissues.
Important limitations exist toward the broader extrapola-
tion of these results to clinical practice. First, PSCs were de-
rived from a single biological specimen (given the difficulty
in obtaining human fetal tissue). While this study is proof-of-
principle demonstration that pancreatic-derived PSCs are
able to undergo osteogenesis, there is no data yet known
regarding potential biological variability based on gender,
age, or other demographic data. In addition, PSCs were ex-
planted in an ectopic environment, rather than in a bone
defect (orthotopic) microenvironment. Studies have sug-
gested that the bone defect niche is critical for MSC-mediated
bone formation. Thus, we consider a second set of experi-
ments of vital importance where PSCs are explanted in a
bone defect scenario to assess true clinical applicability.
Conclusion
Homogenously purified human pericytes exhibited potent
osteogenic potential and direct involvement in new bone re-
generation and angiogenesis; rhNell-1 significantly enhanced
these effects. We demonstrated here the feasibility and efficacy
of combining perivascular stem cells and rhNell-1 on an os-
teoconductive hCBC scaffold to promote better bone forma-
tion and vascular ingrowth. These and similar methods may
be useful in future efforts in bone repair and regeneration.
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